Rosenbæk Frederik, Wehberg Sonja, Pedersen Line Bjørnskov, Nielsen Jesper Bo, Søndergaard Jens
Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.
DaCHE-Danish Centre for Health Economics, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.
Drugs Real World Outcomes. 2025 Mar;12(1):125-133. doi: 10.1007/s40801-024-00479-2. Epub 2025 Jan 10.
Studies on medicinal cannabis (MC) have primarily investigated effects on diseases and symptoms, while there is only sparse knowledge on patients' health-related quality of life. Our aim was, firstly, to compare the health-related quality of life of patients (MC users and non-users) within four specified diagnostic indications (multiple sclerosis, paraplegia, neuropathy, and nausea and vomiting after chemotherapy) with that of patients with other diagnostic indications (MC users only) and the adult population (non-users only). Secondly, we estimate the associations between use of MC and health-related quality of life for patients in the four specified diagnostic indications.
We collected data on quality-adjusted life years (QALYs), using EQ-5D-3L, and patients' self-reported use of MC in a Danish nationwide online survey distributed to 23,846 patients in October 2020. We compared QALY scores of all groups using a two-tailed t-test, listed QALY scores of MC users versus non-users, and investigated associations between QALY score and MC use using unadjusted and adjusted linear regression analyses. Significance level was set to p-value < 0.05.
A total of 9265 patients took part in the survey. All diagnostic indications had a statistically significant lower QALY score than the adult population (0.87). Paraplegia patients had the lowest QALY score, being 0.36 lower, followed by other diagnostic indication (- 0.34), multiple sclerosis (- 0.20), neuropathy (- 0.13), and nausea and vomiting after chemotherapy (- 0.06). MC users had a statistically significant lower QALY score than non-users (0.44 vs 0.74). Users redeeming 1-6 and ≥ 7 MC prescriptions (except for paraplegia patients) had a statistically significant lower QALY score than non-users, ranging between 0.11-0.24 and 0.26-0.32 lower than non-users, accordingly. Although, it should be noted that the number of users was small when stratifying by number of prescriptions.
Patients with either multiple sclerosis, paraplegia, neuropathy, or nausea and vomiting after chemotherapy had a significantly lower health-related quality of life than individuals from the adult population. Users of medicinal cannabis also had a significantly lower health-related quality of life compared with non-users, in all diagnostic indications.
关于药用大麻（MC）的研究主要调查了其对疾病和症状的影响，而对于患者与健康相关的生活质量的了解却很少。我们的目标是，首先，比较在四种特定诊断指征（多发性硬化症、截瘫、神经病变以及化疗后恶心和呕吐）下患者（MC使用者和非使用者）与其他诊断指征患者（仅MC使用者）以及成年人群（仅非使用者）的健康相关生活质量。其次，我们估计在四种特定诊断指征下MC的使用与患者健康相关生活质量之间的关联。
我们在2020年10月向丹麦全国范围内的23846名患者开展的在线调查中，使用EQ-5D-3L收集了质量调整生命年（QALY）数据以及患者自我报告的MC使用情况。我们使用双尾t检验比较了所有组的QALY评分，列出了MC使用者与非使用者的QALY评分，并使用未调整和调整后的线性回归分析研究了QALY评分与MC使用之间的关联。显著性水平设定为p值<0.05。
共有9265名患者参与了调查。所有诊断指征的QALY评分在统计学上均显著低于成年人群（0.87）。截瘫患者的QALY评分最低，比成年人群低0.36，其次是其他诊断指征（-0.34）、多发性硬化症（-0.20）、神经病变（-0.13）以及化疗后恶心和呕吐（-0.06）。MC使用者的QALY评分在统计学上显著低于非使用者（0.44对0.74）。使用1 - 6张和≥7张MC处方的使用者（截瘫患者除外）的QALY评分在统计学上显著低于非使用者，分别比非使用者低0.11 - 0.24和0.26 - 0.32。不过，应当指出的是，按处方数量分层时使用者数量较少。
患有多发性硬化症、截瘫、神经病变或化疗后恶心和呕吐的患者的健康相关生活质量显著低于成年人群。在所有诊断指征下，药用大麻使用者的健康相关生活质量也显著低于非使用者。
